Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_assertion type Assertion NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_head.
- NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_assertion description "[Highly invasive human prostate cancer cells PC-3 were treated with either the methyl donor S-adenosylmethionine (SAM) or methyl DNA-binding domain protein 2 antisense oligonucleotide (MBD2-AS).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_provenance.
- NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_assertion evidence source_evidence_literature NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_provenance.
- NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_assertion SIO_000772 16982764 NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_provenance.
- NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_assertion wasDerivedFrom befree-20150227 NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_provenance.
- NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_assertion wasGeneratedBy ECO_0000203 NP811815.RA3L1ycYRekX5Q-Pt_i0QRAFHSAiyvi1f0IrL5wQhl9E8130_provenance.